

Kiyoyuki Ogata

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1159335/publications.pdf>

Version: 2024-02-01

45
papers

1,910
citations

516710

16
h-index

361022

35
g-index

48
all docs

48
docs citations

48
times ranked

1366
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical, immunophenotypic, and cytogenetic characteristics of high-grade myelodysplastic syndromes with $\text{CD41}^{\text{positive}}$ progenitor cells. <i>Cytometry Part B - Clinical Cytometry</i> , 2023, 104, 98-107.	1.5	1
2	Clinical significance of $\text{CD41}^{\text{positive}}$ blasts in association with a monosomal karyotype in patients with myelodysplastic syndrome treated with azacitidine. <i>British Journal of Haematology</i> , 2020, 189, e144-e147.	2.5	3
3	Revising flow cytometric mini-panel for diagnosing low-grade myelodysplastic syndromes: Introducing a parameter quantifying CD33 expression on $\text{CD34}^{\text{+}}$ cells. <i>Leukemia Research</i> , 2018, 71, 75-81.	0.8	11
4	Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. <i>Oncotarget</i> , 2017, 8, 73483-73500.	1.8	153
5	Prognostic significance of Wilms tumor 1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes. <i>Cancer Biomarkers</i> , 2016, 17, 21-32.	1.7	10
6	Prognostic significance of reproducible immunophenotypic markers of marrow dysplasia. <i>Haematologica</i> , 2014, 99, e8-e10.	3.5	16
7	A Jehovah's Witness with Acute Myeloid Leukemia Successfully Treated with an Epigenetic Drug, Azacitidine: A Clue for Development of Anti-AML Therapy Requiring Minimum Blood Transfusions. <i>Case Reports in Hematology</i> , 2014, 2014, 1-4.	0.4	6
8	Effect of G-CSF on induction of ENA-78 and IL-8 in the patients with malignant lymphoma. <i>Zhongguo Shi Yan Xue Ye Xue Za Zhi / Zhongguo Bing Li Sheng Li Xue Hui = Journal of Experimental Hematology / Chinese Association of Pathophysiology</i> , 2014, 22, 344-8.	0.2	0
9	WT-1 Expression Level In BM Is The Great Prognostic Marker In Three Of Classification IPSS, WPSS, and Latest Revised IPSS(IPSS-R). <i>Blood</i> , 2013, 122, 2795-2795.	1.4	0
10	CD7 Expression On Blasts Of Myelodysplastic Syndromes Is Associated With Apoptosis Resistance With Decreased Expression Of The Proapoptotic Protein Bad and An Independent Unfavorable Prognostic Factor Together With The Revised IPSS Score In Patients. <i>Blood</i> , 2013, 122, 2799-2799.	1.4	3
11	Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study. <i>Haematologica</i> , 2012, 97, 1209-1217.	3.5	136
12	Differences in blast immunophenotypes among disease types in myelodysplastic syndromes: A multicenter validation study. <i>Leukemia Research</i> , 2012, 36, 1229-1236.	0.8	16
13	B7-H1 Molecules on Myeloma Cells Induce Aggressive Cell Behavior. <i>Blood</i> , 2011, 118, 474-474.	1.4	0
14	Standards and Impact of Hematopathology in Myelodysplastic Syndromes (MDS). <i>Oncotarget</i> , 2010, 1, 483-496.	1.8	52
15	Diagnostic utility of flow cytometry in low-grade myelodysplastic syndromes: a prospective validation study. <i>Haematologica</i> , 2009, 94, 1066-1074.	3.5	135
16	Interferon- β and Tumor Necrosis Factor- α Induce An Immunoinhibitory Molecule, B7-H1, Via $\text{NF-}\kappa\text{B}$ Activation in Blasts of Myelodysplastic Syndromes.. <i>Blood</i> , 2009, 114, 2766-2766.	1.4	0
17	Prognostic Significance of WT1 mRNA and Anti-WT1 Antibody Levels in Peripheral Blood in Patients with Myelodysplastic Syndromes.. <i>Blood</i> , 2009, 114, 3821-3821.	1.4	0
18	Diagnostic flow cytometry for low-grade myelodysplastic syndromes. <i>Hematological Oncology</i> , 2008, 26, 193-198.	1.7	33

#	ARTICLE	IF	CITATIONS
19	Flow cytometric parameters with little interexaminer variability for diagnosing low-grade myelodysplastic syndromes. <i>Leukemia Research</i> , 2008, 32, 699-707.	0.8	36
20	Expression and Function of B7.2 and B7-H2 Molecules on Myeloma Cells. <i>Blood</i> , 2008, 112, 2722-2722.	1.4	4
21	Expression of WT-1 mRNA in Peripheral Blood from Myelodysplastic Syndromes. <i>Blood</i> , 2008, 112, 3637-3637.	1.4	0
22	Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndromes: A Prospective Validation Study in Low-Risk Patients with Normal Karyotype. <i>Blood</i> , 2008, 112, 3634-3634.	1.4	1
23	Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. <i>Leukemia Research</i> , 2007, 31, 727-736.	0.8	478
24	B7.2 and B7-H2 Molecules Stimulate Proliferation of Myeloma Cells and Inhibit Anti-Myeloma Immune Responses.. <i>Blood</i> , 2007, 110, 3524-3524.	1.4	0
25	Expression of Functional B7-H1 Molecules on Blasts from Myelodysplastic Syndromes.. <i>Blood</i> , 2007, 110, 2429-2429.	1.4	0
26	Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes. <i>Blood</i> , 2006, 108, 1037-1044.	1.4	153
27	Myelodysplastic Syndromes: Recent Progress in Diagnosis and Understanding of Their Pathophysiology. <i>Journal of Nippon Medical School</i> , 2006, 73, 300-307.	0.9	11
28	Treatment of Relapsing APL Previously Treated with All-trans Retinoic Acid Using Arsenic Trioxide. <i>Nihon Ika Daigaku Igakkai Zasshi</i> , 2006, 2, 152-156.	0.0	0
29	Identification and Hematopoietic Potential of CD45 ⁺ Clonal Cells with Very Immature Phenotype (CD45 ⁺ CD34 ⁺ CD38 ⁺ Lin ⁻) in Patients with Myelodysplastic Syndromes. <i>Stem Cells</i> , 2005, 23, 619-630.	3.2	26
30	Clinical implications of blast immunophenotypes in myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2005, 46, 1269-1274.	1.3	23
31	Flow Cytometric Characteristics of CD34+ Cells in Refractory Anemia: Their Diagnostic Value.. <i>Blood</i> , 2005, 106, 4896-4896.	1.4	0
32	Association between phenotypic features of blasts and the blast percentage in bone marrow of patients with myelodysplastic syndromes. <i>Leukemia Research</i> , 2004, 28, 1171-1175.	0.8	14
33	Identification and Hematopoietic Potential of CD45-Negative Clonal Cells with Very Immature Phenotype (CD45 ⁻ CD34 ⁺ CD38 ⁺ Lin ⁻) in Patients with Myelodysplastic Syndromes.. <i>Blood</i> , 2004, 104, 3426-3426.	1.4	0
34	Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. <i>Blood</i> , 2002, 100, 3887-3896.	1.4	187
35	A Simple Centrifugation Method for Harvesting Myeloblasts. <i>International Journal of Hematology</i> , 2001, 74, 272-276.	1.6	3
36	Flow cytometric assessment of CD15+CD117+ cells for the detection of minimal residual disease in adult acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2000, 108, 710-716.	2.5	21

#	ARTICLE	IF	CITATIONS
37	Effect of Thrombopoietin on Proliferation of Blasts from Patients with Myelodysplastic Syndromes. Stem Cells, 2000, 18, 112-119.	3.2	22
38	Repeated Cycles of G-CSF-Combined Postremission Chemotherapy for Acute Myeloid Leukemia in a First Complete Remission: A Pilot Study. Stem Cells, 1998, 16, 280-287.	3.2	2
39	FAILURE TO DETECT ANTI-HTLV-1 ANTIBODY IN A PATIENT WITH ADULT T-CELL LEUKAEMIA/LYMPHOMA. British Journal of Haematology, 1998, 103, 1207-1208.	2.5	1
40	Plasma Soluble Interleukin-2 Receptors in Patients with Myelodysplastic Syndromes. Leukemia and Lymphoma, 1997, 28, 171-176.	1.3	2
41	Hypofibrinogenemia induced by prednisolone therapy in a patient with chronic lymphocytic leukemia complicated with autoimmune hemolytic anemia. , 1997, 55, 166-167.		6
42	Plasma soluble interleukin-2 receptor level in patients with primary myelodysplastic syndromes: a relationship with disease subtype and clinical outcome. British Journal of Haematology, 1996, 93, 45-52.	2.5	12
43	Interleukin-2 Therapy for Myelodysplastic Syndrome: Does It Work?. Leukemia and Lymphoma, 1995, 17, 411-415.	1.3	4
44	Application of Low-Dose Etoposide Therapy for Myelodysplasia Syndromes. Leukemia and Lymphoma, 1993, 12, 35-39.	1.3	4
45	Two cases of disseminated trichosporon beigelii infection treated with combination antifungal therapy. Cancer, 1990, 65, 2793-2795.	4.1	23